MiRNA expression profiling and clinical implications in prostate cancer across various stages DOI Creative Commons

Zhengjie Xiang,

Tao Lin,

Jian Ling

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Март 5, 2025

This study aims to screen and identify microRNA (miRNA) expression profiles across different stages of prostate cancer (PCa) benign prostatic hyperplasia (BPH) using high-throughput sequencing. The seeks determine whether specific miRNAs show consistent differential various PCa, with the goal identifying potential biomarkers relevant disease progression. In this study, a total 12 specimens PCa BPH were collected from September 2021 June 2022 in Second Affiliated Hospital Nanchang University, 330,006, P.R. China (including 3 early localized tumor, local invasion, distant metastasis tumor BPH). profile miRNA was screened by sequencing technology, differentially expressed between each group bioinformatics analysis. Further targeted site analysis GO enrichment KEGG miRNA-derived genes performed on above miRNAs. Finally, hsa-miR-6715b-3p tissues verified qRT-PCR assay. A 1526 identified through By comparing groups, 228 identified, 100 upregulated 128 downregulated. Additionally, 69 novel predicted. results showed that highly compared tissues. presents preliminary investigation identifies as promising biomarker for Our findings validate high highlight its role critical oncogenic pathways. These provide theoretical foundation further functional studies explore clinical utility therapy resistance progression, contributing growing knowledge miRNA-based PCa.

Язык: Английский

MiRNA expression profiling and clinical implications in prostate cancer across various stages DOI Creative Commons

Zhengjie Xiang,

Tao Lin,

Jian Ling

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Март 5, 2025

This study aims to screen and identify microRNA (miRNA) expression profiles across different stages of prostate cancer (PCa) benign prostatic hyperplasia (BPH) using high-throughput sequencing. The seeks determine whether specific miRNAs show consistent differential various PCa, with the goal identifying potential biomarkers relevant disease progression. In this study, a total 12 specimens PCa BPH were collected from September 2021 June 2022 in Second Affiliated Hospital Nanchang University, 330,006, P.R. China (including 3 early localized tumor, local invasion, distant metastasis tumor BPH). profile miRNA was screened by sequencing technology, differentially expressed between each group bioinformatics analysis. Further targeted site analysis GO enrichment KEGG miRNA-derived genes performed on above miRNAs. Finally, hsa-miR-6715b-3p tissues verified qRT-PCR assay. A 1526 identified through By comparing groups, 228 identified, 100 upregulated 128 downregulated. Additionally, 69 novel predicted. results showed that highly compared tissues. presents preliminary investigation identifies as promising biomarker for Our findings validate high highlight its role critical oncogenic pathways. These provide theoretical foundation further functional studies explore clinical utility therapy resistance progression, contributing growing knowledge miRNA-based PCa.

Язык: Английский

Процитировано

0